Thank you very much. Then, as a high-level summary of why we are in AML, AML is a very aggressive tumor with immunotherapy essentially being the only chance of cure. The only approved immunotherapy currently in AML is bone marrow transplant or hematopoietic stem cell transplant.
Also, in short, HSCT. This is a very high-risk procedure which is inaccessible to most AML patients without a transplant. AML patients face imminent relapse due to residual disease, and actually, the five-year survival rate for AML has been dramatically low, well below 30%.
Why are we relevant?
We offer a safe immunotherapy to reduce relapse by providing immune control over the residual disease.
We have shown that this leads to durable clinical remissions.
But also, very importantly, our product is safe. So we preserve health and quality of life for the patients treated.
This is the 48-month data that I alluded to.
What you see is a nice plateau.
It means that after the initial patients who failed to respond to the therapy suffered from relapse. You see a relatively large population responding with long-term survival. And that is the plateau.
So, the flattening of the curve that you see when you go to the right-hand side indicates that a number of patients have already passed the five-year survival mark.
So, this is a very striking result.
As you know from our previous presentations, we have also looked in a lot of detail into the immune system of the patients.
And we could show that all the patients with a reasonable immune system at the start of treatment were able to build up immune responses against leukemic antigens after treatment with Vididencel.
And also all of them became long-term survivors. So the majority of patients are still alive at 48 months. Median follow-up.
And that is a great outcome.
So that gives us the confidence that we can push vididencel in the broader setting in AML.
And this is an overview of the AML treatment landscape.
Again, HSCT is still the only curative approach, but for the many patients not able to undergo HSCT, there are actually two solutions: one is oral ASA, but oral ASA or oral azacitidine is not very effective. It does give some progression-free survival benefit, but when you look at long-term overall survival, it has very limited effect. And it's still below 30%.
So that patient population is the one we are currently treating in the CADENCE trial. And then at the bottom, you see the patient population which is currently classified as chemo-unfit. So these patients do not receive the classical high intensity chemotherapy. But the combination of azacitidine and venetoclax.
But there is no transplant option.
So the need for immunotherapy to ensure these patients don't relapse is actually even larger than in the chemo-eligible patient population. So this is the reason, plus the fact that the treatment is so effective, it's being used more and more as a first-line treatment, even for patients that are classically classified as chemo fit, means that this is a very fast-growing patient population in need of post-remission immunotherapy.
And this is why we want to expand the positioning of vididencel with the trial, which is a phase one trial addressing azacitidine and treated patients. Overall, the time to market has not changed significantly from our earlier plans, which were to execute a more narrowly defined trial with Oral azacitidine in only MRD positive patients. There are two reasons why we have adjusted the strategy.
First of all, the developments in the AML landscape and the growing opportunity for post-remission immunotherapy are significant factors. So we want to make sure that we adjust to that evolving landscape and are optimally positioned for vididencel in terms of reaching the market and also the overall market potential.
So we have to adapt the execution of a clinical trial to align with the developments in the field, and additionally, the use of MRD has evolved. So where MRD was not part of our phase one trial because it was not commonly used in clinical practice.
In our phase two trial, the ADVANCE II trial we just looked at, we could use it to stratify patients into MRD positive, being a high-risk patient population. But nowadays MRD is used much more continuously to monitor disease. And there's also a variation in MRD levels depending on how the disease is monitored. There are different techniques to do it. In a nutshell, MRD is a very important parameter and part of AML treatment, but the use of it has become a lot more diverse and continuous, rather than just a black and white classification of MRD positive and negative patients.
So all in all, we want to first move beyond MRD positive patients. That is what's currently going on in the CADENCE trial because we treat both positive and negative patients and then assess the patient population very quickly. A growing patient population in need of post-remission immunotherapy is, in principle, also not eligible for transplant. So there is an even higher unmet medical need.
And we really want to ensure that we capture the broader AML opportunity. And also ensuring that our plans to go to market with this product have the best chances of reaching the market, along with securing the recruitment needed to support the phase three trial in the best possible way. So the overall timelines to get to market, we estimate, are not significantly different from the originally planned time to market. We just optimize the chances of getting there.
Then of course, we've had an end-of-phase two meeting with the FDA.
We are also preparing for large-scale GMP production.
We have a manufacturing alliance with a company called North Biologics.
We have entered into the production phase of that alliance, so we are currently evaluating the batches that we have manufactured.
And of course, as soon as we can confirm that we have successfully manufactured and released those batches, we will also notify the market.
But the alliance is on track and a very important part of supporting the late-stage development of vididencel and AML.
Then I will spend a little bit more time on the CML field. And the reason is it's a new field that we aim to enter.
Acute myeloid leukemia and chronic myeloid leukemia do share antigens. That is well documented. But also we have done some pre-clinical work ourselves that we presented last year at the ASH conference, showing that Vididencel actually stimulates immune cells to build up immunity against CML, which is, of course, a starting point for an active immunotherapy to accomplish immune control over the residual disease. But why is it so relevant in CML?
CML is a disease that is driven by a specific oncogene called BCR-ABL. And because this oncogene is so specific, it can also be effectively controlled with inhibitors, Abl1 tyrosine kinase inhibitors, or TKIs.
It means that the disease is, in principle, under control, and that treatment focus has shifted from short-term disease control to quality of life and cost reduction. The quality of life is heavily affected by lifelong TKI usage, so patients really want to try and stop their TKIs, and that is called a treatment-free remission, which has become a key therapy goal in CML. However, if you need to put pressure on the disease with TKIs and you stop using them, in a lot of patients, it quite quickly leads to rising levels of disease within the first 6 to 12 months. In that situation, patients have to be put back on the original or a new generation of TKIs. And the limited success of treatment-free remission (TFR) is basically still an unresolved question. So going back to immune control, CML before the invention of TKIs was treated with hematopoietic stem cell transplant. So with bone marrow transplants, because it's such a dangerous procedure, it's hardly used anymore.
The other immune drug that has been tried in CML is interferon alpha.
But also, it is a very difficult drug to use due to its toxicity and challenging therapeutic window. So people are really looking for new immune therapies to improve TFR success, to ensure that the immune system can control residual disease and that you don't need to take your TKIs for the rest of your life. Now that is a significant unmet medical need.
Also, when you look into the patient numbers on the right-hand side, you will appreciate that CML is a much larger field than AML.
And the main reason is that CML patients live longer. So it's a growing patient population.
The estimated numbers now are roughly 150,000 patients in Europe and 150,000 in the US, so adding up to roughly 300,000 patients in Europe and the US alone.
And almost all these patients have one single goal, which is to live a healthy life without being committed to lifelong drug usage. What we will try to accomplish in 2026 is, first of all, ensuring safety and identifying early signs of efficacy based on the molecular levels of disease that we can monitor.
Then, quite quickly, we plan to step up and start a phase two trial after the initial phase one safety readout. And we will focus in that phase on patients who have previously failed a TFR attempt. The reason to do that is that the failure rate in the first year, at the first TFR attempt, and this is for patients who have had very stable, very low levels of disease allowing them to finally stop their TKIs, is 50%. So this is a good patient population to start and try to pick up the signal that immunotherapy like vididencel allows patients to have a better outcome of their TFR attempt. The start of both of these trials is planned for 2026.
Then moving to the summary in the outlook.
So the positive ADVANCE Phase II data that we have presented, with 48 months of median follow-up, shows that these patients have a chance of durable clinical remissions without having to pay a price of toxicity. The very safe treatment really boosts our confidence to position vididencel more broadly in the AML landscape. And we are currently doing this in the randomized control trial with oral azacitidine. But we will also expand to the chemo-unfit patient population in the trial, in combination with Azacitidine and Venetoclax.
The clinical data we expect from both trials in 2026, plus the anticipated first-line treatment landscape in AML, will guide our optimal go-to-market strategy in AML.
The indication expansion to CML, with a clear rationale based on a very large and growing patient population with unmet medical needs, will open up large additional market potential for vididencel in myeloid blood cancers.
And we have already detailed the clinical trial strategy to advance that indication.
Then I should also mention that in ovarian cancer, we have published positive data in the middle of this year at ASCO.
And we will continue to follow up on these patients. We expect the next readout of the ovarian cancer trial before the year end.
So as near-term clinical milestones, we have the continued long-term follow-up of the ADVANCE II trial, including an update before the year-end.
We have the long-term follow-up data from the ALISON trial in ovarian cancer, and then in the expansion of the positioning of vididencel in the myeloid blood cancer space. We have a number of key readouts planned for 2026, including the CADENCE trial readout based on the first 20 patients in the trial. The trial readout based on initial safety and efficacy data, and the initial safety and feasibility data in CML, is, of course, the first big step into the remainder of the phase one trial, but also the start of the phase two trial. So with that, I would like to hand it over to the Q&A session and am welcome to answer any questions.